Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update
Competitor Analysis: Biosimilar and Biosuperior Anti-Her2 Antibodies – 2016 Update
This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-Her2 Antibodies 2016 updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting Her2 in comparison with originator anti-Her2 antibodies to treat solid tumors as of May 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in development of Her2 targeting antibodies for treatment of Her2 positive breast and gastric cancer. In addition, the report lists company-specific R&D pipelines of biosimilar and biosuperior Herceptin antibodies.
Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This Competitive Intelligence Report about Biosimilar and Biosuperior Anti-Her2 Antibodies 2016 updates the competitive landscape of biosimilar and biosuperior therapeutic antibodies targeting Her2 in comparison with originator anti-Her2 antibodies to treat solid tumors as of May 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
The report includes a compilation of currently active projects in development of Her2 targeting antibodies for treatment of Her2 positive breast and gastric cancer. In addition, the report lists company-specific R&D pipelines of biosimilar and biosuperior Herceptin antibodies.
Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
1. 2015 ANTI-HER2 ANTIBODY SALES
2. ORIGINATOR ANTI-HER2 ANTIBODIES
Herceptin Approved Indications & Pipeline
Perjeta Approved Indications & Pipeline
Kadcyla Approved Indications & Pipeline
3. BIOSUPERIOR ANTI-HER2 ANTIBODIES
3RD GENERATION ANTI-HER2 ANTIBODIES
Bispecific Anti-Her2 Antibodies
Anti-Her2 Antibody-Drug Conjugates, Immunotoxins, Immunocytokines & Radiopharmaceuticals
4. BIOSIMILAR ANTI-HER2 ANTIBODIES
Herceptin Biosimilar Antibodies
Developments in Regulated Markets
Development in Less Regulated Markets
Perjeta Biosimilar Antibodies
5. CORPORATE ANTI-HER2 BIOSIMILAR & BIOSUPERIOR ANTIBODY PIPELINES
2. ORIGINATOR ANTI-HER2 ANTIBODIES
Herceptin Approved Indications & Pipeline
Perjeta Approved Indications & Pipeline
Kadcyla Approved Indications & Pipeline
3. BIOSUPERIOR ANTI-HER2 ANTIBODIES
3RD GENERATION ANTI-HER2 ANTIBODIES
Bispecific Anti-Her2 Antibodies
Anti-Her2 Antibody-Drug Conjugates, Immunotoxins, Immunocytokines & Radiopharmaceuticals
4. BIOSIMILAR ANTI-HER2 ANTIBODIES
Herceptin Biosimilar Antibodies
Developments in Regulated Markets
Development in Less Regulated Markets
Perjeta Biosimilar Antibodies
5. CORPORATE ANTI-HER2 BIOSIMILAR & BIOSUPERIOR ANTIBODY PIPELINES
